在罗马尼亚发展癌症生物银行:了解评估生物标本临床数据集的知识和建议

Q2 Medicine Medicine and Pharmacy Reports Pub Date : 2023-10-01 Epub Date: 2023-10-26 DOI:10.15386/mpr-2646
Liliana Policiuc, Cecilia Bica, Cristina Ciocan, Daniel Corneliu Leucuta, Andreea Nutu, Ioana Berindan-Neagoe
{"title":"在罗马尼亚发展癌症生物银行:了解评估生物标本临床数据集的知识和建议","authors":"Liliana Policiuc, Cecilia Bica, Cristina Ciocan, Daniel Corneliu Leucuta, Andreea Nutu, Ioana Berindan-Neagoe","doi":"10.15386/mpr-2646","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of 'biobanking' and 'personalized medicine' in three categories of participants in the development of a biobank - health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample.</p><p><strong>Methods: </strong>A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank - clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40).</p><p><strong>Results: </strong>The survey indicated that the terms 'biobank' and 'personalized medicine' are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank.</p><p><strong>Conclusions: </strong>The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease.</p>","PeriodicalId":18438,"journal":{"name":"Medicine and Pharmacy Reports","volume":" ","pages":"392-399"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642746/pdf/","citationCount":"0","resultStr":"{\"title\":\"Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens.\",\"authors\":\"Liliana Policiuc, Cecilia Bica, Cristina Ciocan, Daniel Corneliu Leucuta, Andreea Nutu, Ioana Berindan-Neagoe\",\"doi\":\"10.15386/mpr-2646\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of 'biobanking' and 'personalized medicine' in three categories of participants in the development of a biobank - health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample.</p><p><strong>Methods: </strong>A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank - clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40).</p><p><strong>Results: </strong>The survey indicated that the terms 'biobank' and 'personalized medicine' are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank.</p><p><strong>Conclusions: </strong>The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease.</p>\",\"PeriodicalId\":18438,\"journal\":{\"name\":\"Medicine and Pharmacy Reports\",\"volume\":\" \",\"pages\":\"392-399\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642746/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine and Pharmacy Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15386/mpr-2646\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine and Pharmacy Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15386/mpr-2646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的。在罗马尼亚个性化医疗和生物银行的新颖性背景下,迫切需要分析该领域关键参与者的知识程度。本研究旨在调查在生物银行开发过程中,卫生专业人员(临床医生/诊断医师)、科研人员和患者这三类参与者对“生物银行”和“个性化医疗”的理解,以确定信息水平方面可能存在的错误。本研究的次要目的是确定关键因素和相关数据,这些因素和数据应详细记录在伴随生物样本的临床数据集中。方法。本研究共纳入120名参与者,他们被分为三类,代表了癌症生物库开发和管理的关键角色——临床医生(n=40)、科研人员(n=40)和肿瘤患者(n=40)。结果。调查表明,只有一部分患者不知道“生物银行”和“个性化医疗”这两个术语,而其他两组患者已经知道这些术语。第二份问卷允许在提供生物样本以纳入癌症生物库时填写推荐的临床数据集。结论。在罗马尼亚建立符合道德和操作标准的生物库时,患者和医疗保健专业人员的信任非常重要,因为人工智能和数据库的发展允许先进的知识和来自不同数据库的发现的联系,因此使个性化医疗的概念更接近临床实践。该数据集中包含的信息将被整合并构成一个全面的生物银行数据库。所有这些方面都是为了增加样本在癌症研究中的效用,因为清晰注释的样本以及前瞻性数据带来了有价值的知识,有助于科学研究人员和临床医生在分子改变与特定患者或疾病的表型之间建立临床联系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Developing cancer biobanks in Romania: understanding the knowledge and recommendations in assessing a clinical dataset for biospecimens.

Background and aims: In the context of the novelty of personalized medicine and biobanking in Romania, there is an acute need to analyze the degree of knowledge of the key actors in the domain. The present study sought to investigate the understanding of 'biobanking' and 'personalized medicine' in three categories of participants in the development of a biobank - health professionals (clinicians/diagnosticians), scientific researchers, and patients, in order to identify possible faults regarding the level of information. The secondary objective of this study was to identify key elements and relevant data that should be detailed in the clinical dataset that accompanies a biological sample.

Methods: A total of 120 participants were included in this study that were divided into three categories that represent key actors in the development and management of a cancer biobank - clinicians (n=40), scientific researchers (n=40), and oncology patients (n=40).

Results: The survey indicated that the terms 'biobank' and 'personalized medicine' are unknown only in a proportion of patients, while for the other two groups, these terms are already known. The second questionnaire allowed the arrangement of a recommended clinical dataset to be filled when a biological sample is provided to be included in a cancer biobank.

Conclusions: The trust of patients and healthcare professionals in building biobanks that adhere to ethical and operational standards in Romania is important, as the development of artificial intelligence and databases allows advanced knowledge and connection of findings from different databases and, therefore, brings the concept of personalized medicine closer to the clinical practice. The information included in this dataset will be integrated and constitutes a comprehensive biobank database. All these aspects are meant to increase the utility of the specimens in cancer research, as clearly annotated samples, along with prospective data, bring valuable knowledge that helps scientific researchers and clinicians make the clinical connection between the molecular alterations and the phenotype of particular patients or a disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medicine and Pharmacy Reports
Medicine and Pharmacy Reports Medicine-Medicine (all)
CiteScore
3.10
自引率
0.00%
发文量
63
期刊最新文献
5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity. Artificial Intelligence and medical specialties: support or substitution? Clonal distribution and molecular characterization of Staphylococcus aureus isolated strains in Chania and Heraklion, Crete. Exploring anesthesia-related complications in pediatric neurosurgery: a comparative analysis of the sitting and park-bench positions. Genetic and clinical factors influencing CF-associated liver disease: the impact of SERPINA1 variants and CFTR genotypes in Romanian pediatric cystic fibrosis patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1